Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science ...
Zevra Therapeutics (NASDAQ:ZVRA – Free Report) had its target price boosted by Canaccord Genuity Group from $23.00 to $25.00 ...
It’s been just six months since Zevra Therapeutics scored an FD | Niemann-Pick disease type C therapy Miplyffa became ...
Canaccord analyst Sumant Kulkarni raised the firm’s price target on Zevra Therapeutics (ZVRA) to $25 from $23 and keeps a Buy rating on the ...
CELEBRATION, Fla. (AP) — CELEBRATION, Fla. (AP) — Zevra Therapeutics, Inc. (ZVRA) on Tuesday reported a loss of $35.7 million in its fourth quarter. The Celebration, Florida-based company said it had ...
Cantor Fitzgerald reissued their overweight rating on shares of Zevra Therapeutics (NASDAQ:ZVRA – Free Report) in a research ...
(AP) — Zevra Therapeutics ... Zacks Investment Research was for a loss of 39 cents per share. The specialty pharmaceutical company posted revenue of $12 million in the period, exceeding Street ...
(AP) — Zevra Therapeutics ... Advertisement Article continues below this ad The specialty pharmaceutical company posted revenue of $12 million in the period, exceeding Street forecasts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback